A phase III trial of setmelanotide in patients with leptin receptor (LepR) deficiency obesity
Phase of Trial: Phase III
Latest Information Update: 27 Jun 2017
At a glance
- Drugs Setmelanotide (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- 27 Jun 2017 According to a joint media release by Rhythm and Camarus, status changed from planning to recruiting.
- 20 Feb 2017 New trial record
- 16 Feb 2017 According to a Rhythm Pharmaceuticals media release, this trial is expected to initiate in 2017.